|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The hypothesis in question can be tested if the DNA of P. gingivalis or the antibodies against P. gingivalis can be detected in patients with the p53 arginine mutation.If this hypothesis is true, it could reveal the real cause of pancreatic cancer, which is a fatal disease.
|
26617937 |
2015 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Frequently reported genome alterations were: the +3q27 and +8q24 mutations of TP53 for esophageal cancer; +20q13 for gastric cancer; -18q22 and +20q12-q13 mutations of APC, TP53 and KRAS for colorectal cancer, and the -18q22 mutation of KRAS and TP53 for pancreatic cancer.
|
19023234 |
2008 |
|
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
We investigated the prevalence of germline mutations in APC, ATM, BRCA1, BRCA2, CDKN2A, MLH1, MSH2, MSH6, PALB2, PMS2, PRSS1, STK11, and TP53 in patients with pancreatic cancer.
|
25479140 |
2015 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Also in the light of the demonstrated cooperation of ras and p53 gene alterations in the transformation of cultured cells, our data suggest that p53 mutation is one of the genetic defects that may have a role in the pathogenesis of a proportion of pancreatic cancers.
|
8494051 |
1993 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Alterations in the p53 and Rb-1 genes may be important features in the development of human pancreatic cancer.
|
1630814 |
1992 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Western blot analysis and siRNA silencing studies in mutant as well as p53 null cells highlighted a mechanism involving p73 which is also known to be under the regulation of MDM2, and unlike p53, it is rarely mutated in PC.
|
20156675 |
2010 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
These data show that in some cases of chronic pancreatitis mutations in the p53 gene occur without morphological evidence of pancreatic cancer.
|
9529487 |
1998 |
|
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
Intraperitoneal delivery of a retroviral p53 vector may provide a novel treatment approach for peritoneal carcinomatosis from pancreatic cancer.
|
9706132 |
1998 |
|
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
Analysis by scanning electron microscopy revealed that these supernumerary structures are devoid of centrioles, a result significantly different from observations in aneuploid pancreatic cancer cell lines and in Trp53 or Brca1 deficient MEFs.
|
19768832 |
2009 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
To elucidate whether and how mutant p53 acquires its gain-of-function, mutant p53 is inducibly knocked down in the SW480 colon cancer cell line, which contains mutant p53(R273H/P309S), and the MIA PaCa-2 pancreatic cancer cell line, which contains mutant p53(R248W).
|
18701504 |
2008 |
|
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
Together, our data support the critical role of autophagy in pancreatic cancer and show that inhibition of autophagy may have clinical utility in the treatment of these cancers, independent of p53 status.
|
24875860 |
2014 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
In this study we evaluated whether the mutation rate of the TP53 and p16INK4a genes of pancreatic cancers differs in pancreatic cancer patients with and without multiple primaries.
|
11075991 |
2000 |
|
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
Our study first demonstrated that overexpression of CRT contributed to the development and progression of PC through MEK/ERK-signaling pathway but independent of p53.
|
24264800 |
2014 |
|
Malignant neoplasm of pancreas
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Both failed to specifically suppress p53 protein production in a cell-free assay system or to have any effect on mutant p53 expression by human pancreatic cancer cell lines.
|
7880719 |
1995 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Advances in the understanding of pancreas cancer biology have been made over the past decade, including the discovery of critical mutations in oncogenes (i.e., K-Ras) as well as the loss of tumor suppressor genes, such as TP53 and p16(INK4).
|
16818496 |
2006 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
From these, K-ras mutations detected in blood, stool and bile juice of patients at risk for pancreatic cancer seem to be more promising than p53 alterations as a more later step in carcinogenesis, although they are neither yet well established nor standardised by reliable assays.
|
10436809 |
1999 |
|
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
Trp53(+/-) mice overexpressing Tgfalpha in a pancreas-specific manner represent a well-established animal model for pancreatic cancer.
|
14506698 |
2003 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
In summary, our observations strongly indicated that, similarly to 2D monolayer culture, RUNX2 gene silencing increased GEM sensitivity of MiaPaCa‑2 spheres and highlighted the therapeutic potential of RUNX2 in pancreatic cancer with p53 mutation.
|
29620279 |
2018 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We previously observed an association between TP53 haplotypes based on four polymorphisms (rs17878362, rs1042522, rs12947788, and rs17884306) and the risk of colorectal and pancreatic cancer.
|
26226484 |
2015 |
|
Malignant neoplasm of pancreas
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Taken together, our data indicate that PRIMA-1 induces apoptosis in p53 mutant pancreatic cancer cells by promoting the re-activation of p53 and inducing proapoptotic signaling pathways, providing in vitro evidence for a potential therapeutic approach in pancreatic cancer.
|
24838627 |
2014 |
|
Malignant neoplasm of pancreas
|
0.800 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Restoration of transforming growth factor-beta signaling enhances radiosensitivity by altering the Bcl-2/Bax ratio in the p53 mutant pancreatic cancer cell line MIA PaCa-2.
|
11694525 |
2002 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
In this study we examined the potential of three intrinsically fluorescent benzo[α]phenoxazines or BPZs (R=Cl, CH3, H) to induce cytotoxic autophagy in chemo and apoptosis-resistant, KRAS and p53 mutated pancreatic cancer model cell line, MIAPaCa-2.
|
27349450 |
2017 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Detection of KRAS or p53 mutation in plasma is not an effective screening tool for pancreatic cancer because accumulation of multiple mutations is required for malignant transformation in the pancreas.
|
29303908 |
2018 |